Open company graph database — free web & API
Login

Tomita Pharmaceutical Co., Ltd.

富田製薬株式会社
Ticker
—
Listed market
—
Country
Japan
Employees (non-consolidated)
638
Related companies
3
§01

Basic information

BASIC
Head office
1-85 Maruyama, Seto-cho, Naruto-shi, Tokushima Prefecture 771-0360, Japan
Chief executive
Junhiro Tomita
Capital
96,000,000
Employees (non-consolidated)
638 people
Employees (consolidated)
Start date
1955-07-08
End date
§02

Websites

1 DOMAINS
§03

Business

9
Active pharmaceutical ingredients and additivesFood additivesCosmetic raw materialsOther chemicalsFersov® (Ferrous pyrophosphate)Multifunctional excipient 'Fluorite®'Oil refining agent 'Briskor®'Biomaterial HydroxyapatiteAdsorbent Tomita-AD
§04

Related companies

3 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Mitsubishi UFJ Bank Ltd.
Bank
Japan Federation of Co-operative Central Bank
Bank
Tokushima Taisho Bank Ltd.
Bank
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

123 EVENTS

The founder, Kyuzaburo Tomita, began full-scale research in Shizuoka on a manufacturing process using bittern as a raw material. His goal was to mass-produce magnesium carbonate for pharmaceutical use at good quality and low cost, hopeful to make it as a replacement for imported expensive products.Sources

In the same year, he started manufacturing and selling cough medicine “Lauryl Sulfate Water” and “Lauryl Oil” from the Japanese evergreen oak, and invests all of the profits from the sales in researching the manufacturing process of magnesium carbonate.Sources

Founder Kunizaburo Tomita began serious research in Shizuoka on a method using bitter juice as a raw material to mass-produce high-quality, inexpensive magnesium carbonate for medicinal use, which at the time relied on expensive imported products.Sources

That same year, he manufactured and sold the cough suppressant 'Loriil Kels Water' and 'Loriil Oil' from Oobashi, investing all sales profits into research on the magnesium carbonate production method.Sources

Moved in Shizuoka Prefecture in order to continue to procure bittern. He also began research into sodium carbonate, the main raw material for magnesium carbonate.Sources

After repeated failures, they achieved the creation of magnesium carbonate, but it had less bulk than the intended result. The company attempted to market this product as “heavy magnesium carbonate” but it was not accepted in a market.Sources

To procure bitter juice, he moved within Shizuoka Prefecture and also worked on research into the main raw material, sodium carbonate.Sources

After repeated failures, the produced magnesium carbonate differed from the intended product and had low potency. It was sold as 'Heavy Magnesium Carbonate', but it was not accepted by the market.Sources

Pure magnesium carbonate production was at last achieved after thorough review of the manufacturing process and development of equipments. Acetic acid, sulfuric acid, nitric acid, ether, and other chemicals and also under production.Sources

By revising the process and developing machinery and equipment, the long-awaited pure magnesium carbonate production method was completed. Acetic acid, sulfuric acid, nitric acid, ether, and others were also produced.Sources

Kyuzaburo (age 28) went to the Jishu salt fields (near the Seto Inland Sea) in search of a large amount of bittern. At that time, in the Jishu salt fields, after salt was extracted from seawater, the remaining bittern was discarded into the sea.Sources

The factory operation in Kiga, Shizuoka failed in mass production and was closed, but the business and research continued.Sources

At 28, Kunizaburo traveled to the Tokushū salt fields (near the Seto Inland Sea) to investigate large quantities of bitter juice. At that time, the Tokushū salt fields discarded the remaining bitter juice into the sea after extracting sea salt from seawater.Sources

The factory in Shizuoka (Kiga) failed to achieve mass production and was closed, but the business and research continued.Sources

Magnesium carbonate became official for British Pharmacopoeia and ether became officlal for US Pharmacopeia.Sources

Magnesium carbonate obtained British Pharmacopoeia approval, and ether obtained U.S. Pharmacopoeia approval.Sources

To secure bitter juice, a solar salt production facility was built in Hamana, Shizuoka Prefecture, and the business began, but securing the necessary land and the collapse of salt prices affected the main pharmaceutical business, so it was discontinued.Sources

The Japanese Pharmacopoeia was enacted and promulgated (and went into effect the following year), and magnesium carbonate and magnesium sulfate were approved. It was touted that “the only domestic products that conformed to the pharmacopoeia were Tomita’s products.”Sources

The credibility of the trademark “Ⓣ” mark increased, and demand for the product increased day by day. After years of struggling financially, Tomita was able to turn a profit.Sources

Years later, Kyuzaburo was quoted as saying, “The heavens did not abandon the struggling man, but gave him a great boon. What was this boon? It was the enactment of the Japanese Pharmacopoeia in June of 1887.”Sources

The Japanese Pharmacopoeia was promulgated (effective the following year), and magnesium carbonate and magnesium sulfate passed. It received praise: 'Among products that meet the Pharmacopoeia, the only domestic product is Tomita's.'Sources

The trust in Tomita Pharmaceutical's trademark (Ⓣ) grew, and demand increased day by day. After years of hardship, profits were realized.Sources

Later, Kunizaburo said, 'Heaven does not abandon those who toil hard, and indeed it bestowed a great blessing. What is that blessing? It is the promulgation of the Japanese Pharmacopoeia in June 1886 (Meiji 19).'Sources

Just as the business was beginning to take off, the factory burnt down in a fire. The company lost not only its machinery but also all of its research materials, and had no choice but to cease operations.Sources

Just as the business began to take off, the factory burned down completely. All machinery and research materials were lost, and the business was discontinued.Sources

Re-examined the Jishu salt fields in the Setouchi area. Reached the conclusion that establishing a pharmaceutical plant in the Jishu salt fields would be an efficient way to secure bittern.Sources

Re-examined the Tokushū salt fields. Concluded that establishing a pharmaceutical factory in the Tokushū salt field area would allow efficient securing of bitter juice.Sources

Succeeded in separating and producing potassium chloride from bittern for the first time in Japan.Sources

First in Japan to successfully separate and produce potassium chloride from bitter juice.Sources

Kyuzaburo moved to Naruto, Tokushima Prefecture and built a factory in Seto-Cho (now Naruto City).Sources

Kunizaburo moved to Naruto, Tokushima Prefecture, and built a factory in present-day Seto Town, Naruto City.Sources

Established the 'Tomita Marine Salt Production Plant'. Began full-scale production of magnesium carbonate and magnesium sulfate.Sources

Tomita Marine Products Industry was established on January 1. Full-scale production of magnesium carbonate and magnesium sulfate began.Sources

Participates in the 4th National industrial Exhibition held in Kyoto. Here, Tomita showcased their magnesium carbonate, magnesium carbonate(heavy), magnesium sulfide, magnesium sulfate, potassium iodide, potassium bromide, sodium bromide, and sodium chloride.Sources

A stone oven was used to extract salt from soil by boiling seawater in stone cauldrons. The salt was refined by removing the sodium sulfate contained within. It was named “Japanese salt” and sold.Sources

The name of the company was changed to Tomita Pharmaceutical Factory.Sources

Succeeded in separating and producing potassium chloride from bittern whose demand was increased due to Japan’s supply shortage after WWI.Sources

Against the backdrop of shortages in national material procurement during World War I, successfully separated and produced potassium chloride from the bitter broth as demand rose.Sources

Started focusing on the poduction of magnesium carbonate, potassium chloride, and bromine by reorganizing products line-up and establishing a new factory.Sources

By reorganizing products and establishing a factory, focus on the production of magnesium carbonate, potassium chloride, and bromine.Sources

Responding to increased demand for magnesium carbonate due to the development of the rubber industry, successfully produced magnesium carbonate for transparent rubber processing.Sources

After WWI, the production of sodium chloride, which was rapidly in short supply, was started with the permission of recrystallized salt production.Sources

After World War I, obtained special permission No.1 to resume production of sodium chloride, which had become rapidly scarce, and began manufacturing.Sources

The invention of the concrete assembly-type Numai-dai (swamp well platform) contributed to the improvement of salt manufacturing technology in the Irihama typesalt fields*, and a subsidy was granted to the company for promoting the propagationand industrial development of the industry.Sources

The devised concrete modular pond platform contributed to improving salt production technology in the Nibahama-style saltworks, leading to the award of a promotion of industry grant.Sources

Kyuzaburo (age 76) left for an 8-month tour of Germany for pharmaceutical research.Sources

Kusaburo departed for an eight-month Western inspection (Germany) for pharmaceutical research. Kusaburo (76 years old).Sources

In response to the postwar recession, Kyuzaburo researched magnesium carbonate manufacturing methods. He succeeded in the industrialization of a manufacturing method of utilizing caustic lime as a starting material, and also perfected the manufacturing method for magnesium oxide.Sources

In response to the post-World War I recession, researched the production method of magnesium carbonate. Successfully industrialized the lime-based method and completed the production method for magnesium oxide.Sources

Tomita Pharmaceutical Factory was reorganized into a corporation and establishes itself as Tomita Seiyakusho Co.,Ltd.Sources

Reorganized the Tomita Pharmaceutical Factory into a corporate organization and established 'Tomita Pharmaceutical Co., Ltd.'Sources

Sales of the health conditioning agent Robaston.Sources

Responding to the issuance of the “Order for Control of Daily Necessities,” the product of “bittern potassium salt” was sold as a fertilizer. Production was discontinued three years later due to Strategic Industries Control Act of the bittern industry.Sources

A ceremony commemorating Tomita’s 50th anniversary was held at the newly renovated magnesium sulfate plant.Sources

Received an order from the Navy to produce strontium.Sources

Received an order from the navy to produce strontium.Sources

The company began marketing vaccines for oral dysentery, typhoid, and paratyphoid, as well as an injectable vitamin B2 and the prophylactic drug penicillin.Sources

The four large chimneys that had served as a symbol of the company were removed from its building during the war for fear that they would be used as air raid markers.Sources

Sold oral dysentery vaccine, typhoid vaccine, paratyphoid vaccine, as well as injectable vitamin B2 and preventive penicillin.Sources

The four large chimneys that were the company's symbol were removed due to concerns that they would serve as targets during wartime air raids.Sources

Established 'Tomita Pharmaceutical Co., Ltd.' with Tomita Sadazaburo as representative director.Sources

The Nankai Earthquake in 1946.Sources

In 1947, the company began marketing “Macron tablets,” an anthelmintic with an active ingredient of seaweed extract.Sources

A fire at a magnesium carbonate drying plant in 1948.Sources

Using by-products from textile mills, the company began producing anhydrous sodium sulfate in 1949.Sources

A fire at a salt brine refinery in 1949.Sources

Typhoon Jane in 1950.Sources

During this five-year period, the company researched and developed a wide range of products for which it was licensed to manufacture, including barium chloride, camphor oil injection, barium sulfate, Ringer’s solution, saline solution, vitamin B2 injection solution, and saline tablets.Sources

Using by-products from textile mills, the company began producing sodium sulfide in 1951.Sources

Tomita Pharmaceutical Co., Ltd. was established on July 8 (using the current Japanese name), with Teizaburo Tomita as representative director.Sources

The company was affected by the bankruptcy of its main customers and the resulting dishonored check. Even during the high-growth period of the Japanese economy, Tomita’s business conditions remained tense.Sources

As a challenge in a new field, the company developed and sold an organic hair straightening agent, “Ammonium Thioglycolate.”Sources

Magnesium silicate was developed and marketed as an antacid.Sources

Developed high-purity magnesium oxide for silicon steel sheets.Sources

Suffered severe damage from the second Muroto typhoon. Production of “Ammonium Thioglycolate” was discontinued due to damage to the manufacturing equipment caused by the second Muroto Typhoon.Sources

Started trade with Korea and Taiwan.Sources

The company developed aluminum hydroxide gel and synthetic aluminum silicate in order to enter the field of antacid agents in earnest.Sources

Developed magnesium metasilicate aluminate as an antacid agent.Sources

Started trade with Hong Kong, Vietnam, the Philippines, and Australia.Sources

Management policy was formulated into a long-term plan under the guidance of Tanabe Management Counseling Center. Established “Company Policy,” “Creed,” and “Corporate Mission Statement.” A management policy presentation meeting was held, and the corporate structure was enhanced and improved.Sources

Developed “Wakame Tea” using wakame seaweed, a specialty of Naruto City, and registered it as a trademark. However, the market response was weak and the company abandoned the commercialization of the product.Sources

Succeeded in developing high-purity Sodium Chloride for use in artificial dialysis.Sources

Developed and began sale of Uni-Meisui, a natural liquor clarifier made from carrageenan.Sources

Established Tokushima Plant in Tokushima Pharmaceutical Industrial Park to strengthen facilities to meet increasing demand for antacids.Sources

With the enactment of the “Pharmaceutical GMP” ministerial ordinance, the company worked to estabilish a quality system from the point of both management system and equipment control.Sources

Research was initiated on the production of gluconic acid from mold fungi.Sources

Started joint research with the Agency of Industrial Science and Technology and the Shikoku National Industrial Research Institute on pore size control technology for inorganic salts.Sources

Started production and sale of the synthetic adsorbent TOMIX-AD and high-performance adsorbent Q-Fine series.Sources

Tomita was contracted to produce powdered artificial seawater “Marine Art” in collaboration with Senju Pharmaceutical Co., Ltd.Sources

Celebrated 100 years of business.Sources

Celebrated its 100th anniversary.Sources

Mass production of a powdered dialysate for overseas markets began.Sources

Mass-produced powdered dialysis agents for overseas markets.Sources

The first powdered dialysate production facility was completed.Sources

Full-scale production began.Sources

Completed Building 1 of the powdered dialysis agent facility.Sources

Commenced full-scale production of powdered dialysis agents.Sources

Launched sales of powdered dialysate KIDOLIME T-30.Sources

Launched sales of the powdered dialysis agent 'Kidryum T-30'.Sources

A second powdered dialysate production facility was completed.Sources

A system to increase production was established.Sources

Completed Building 2 of the powdered dialysis agent facility.Sources

Established a scale-up system for powdered dialysis agent production.Sources

Began operation of the Kawasaki Plant, a plant dedicated to the production of sodium chloride.Sources

Completion of magnesium oxide production building.Sources

Commenced operations of the Kawasaki plant, dedicated to sodium chloride production.Sources

Magnesium oxide production building completed.Sources

Opened a representative office in New Jersey, USA.Sources

Completion of a manufacturing plant dedicated to the production of FLORITE®.Sources

New Jersey U.S. branch office established.Sources

Fluorite-specific manufacturing plant completed.Sources

Tomita R&D Center was completed. Tomita focused on the development of new products as an R&D-oriented company.Sources

Tomita R&D Center completed. Focused on new product development as a research and development company.Sources

A third powdered dialysate production facility was completed.Sources

Powder dialysis agent Building 3 completed.Sources

Compliance Policy and Action Guidelines were established, as well as the Compliance Committee.Sources

Compliance basic policy and code of conduct established.Sources

Compliance Committee established.Sources

A new QC center was established, strengthening sales of pharmaceutical raw materials to overseas customers.Sources

Established QC Center and strengthened overseas pharmaceutical raw material sales.Sources

Quality Policy was established.Sources

Quality policy established.Sources

Committed to compliance with laws and making products with quality as the top priority.Sources

§07

News

9 ARTICLES

Tomita Pharmaceutical Selected for Wage Increase Support Grant in Fifth Public OfferingSources

Tomita Pharmaceutical Co., Ltd. has been selected for the Ministry of Economy, Trade and Industry's "Large-Scale Growth Investment Subsidy for Labor Efficiency and Wage Increase for Medium and Small Enterprises and Startups" in its fifth public offering. The grant will invest in factory restructuring projects for dialysis solutions, pharmaceutical raw materials, and other products, aiming to raise the average employee wage increase rate to 7.0%.

Announcement of Participation in AAPS 2026 PHarmSCi 360Sources

Futamura Pharmaceutical will exhibit at the AAPS 2026 PHarmSCi 360 held in New Orleans, USA, from October 25 to 28, 2026. During the event, we will introduce our product lineup, technologies, and solutions. The venue is the Ernest N. Morial Convention Center, and our booth number is 1436.

Announcement of participation in Food Development Expo 2026Sources

Futamata Pharmaceutical will exhibit at Food Development Expo 2026, held at Tokyo Big Sight from October 14 to 16, 2026. We will introduce nutrition-enhancing products and technologies such as Fluorite and Fersoob, and demonstrate at Booth A-034. Presentations on the functional aspects of Fluorite will be conducted on October 14 and 15.

Announcement of Participation in CPHI Milan 2026Sources

Futamura Pharmaceutical Co., Ltd. will exhibit at CPHI Milan 2026, held at Fiera Milano in Milan, Italy, from October 6 to 8, 2026. At Booth 3D51 in Hall 3, we will showcase our product lineup, technology, and services.

International Sales Department Osaka Office Headquarters RelocationSources

In order to strengthen overseas business structure and enhance internal collaboration, the Osaka Office of the International Sales Department of the Sales Headquarters will be relocated to the headquarters. The start date of operations at the new location is October 1, 2026.

Interview of Research Staff Published in Tokushima ShimbunSources

An interview with Takashi Takemoto, a research staff member of the Research Headquarters, was published in the April 11, 2026 edition of the Tokushima Shimbun morning paper titled "Challenge and Growth." The article introduces his research experience in graduate school, the circumstances that led him to pursue inorganic chemistry after joining the company in 2021, and his current work on developing drugs for kidney diseases. It also highlights the environment where he can be involved in everything from market research to manufacturing and analysis, and discusses the rewards of research.

Announcement of Participation in CPHI FrankfurtSources

Futamura Pharmaceutical Co., Ltd. will exhibit at CPHI Frankfurt, which will be held at Messe Frankfurt in Germany from Tuesday, October 28, 2025, to Thursday, October 30, 2025. Booth number is 11.0B24.

Exhibiting at Food Development Exhibition 2025Sources

Tomita Pharmaceutical will exhibit at Food Development Exhibition 2025, held at Tokyo Big Sight from October 15 to 17, 2025. The company will introduce functional powders, nutritional enrichment products, and its technologies. The booth is A-034 in the Atrium Hall.

Naming Rights Agreement with Naruto University of EducationSources

Futamura Pharmaceutical has entered into a naming rights agreement with the National University Corporation Naruto University of Education, and the facility’s nickname became “Futamura Pharmaceutical Manabi Library.” The contract period is from June 1, 2025 to March 31, 2028. As part of its community contribution activities, the company intends to actively participate and cooperate in future opportunities and events.

§08

Public records

GOV
National Tax Agency basic information1480001005057
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
富田製薬株式会社
Trade name (kana)
トミタセイヤク
Name in English
Tomita Pharmaceutical Co.,Ltd.
Corporation type
301
Address
〒771-0360 徳島県鳴門市瀬戸町明神字丸山85番地1
Postal code
7710360
Prefecture code
36
City code
202
Address outside Japan
Prefecture in English
Tokushima
City in English
85-1,Maruyama,Akinokami,Seto-cho, Naruto shi
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2025-06-30
Change date
2019-04-11
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
平成31年3月31日徳島県鳴門市瀬戸町明神字丸山85番地1株式会社富田製薬所(9480001005058)を合併
Latest record
1
Excluded from search
0
Processing type
71
Correction type
1
Trade name image ID
Address image ID
Sequence number
5009530
METI gBizINFO1480001005057
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
1480001005057
Trade name
富田製薬株式会社
Trade name (kana)
トミタセイヤク
Trade name (alphabet)
Tomita Pharmaceutical Co.,Ltd.
Registry closure date
Reason for registry closure
Registered address
徳島県鳴門市瀬戸町明神字丸山85番地1
Postal code
7710360
Prefecture
徳島県
Prefecture code
36
City or district
鳴門市
City code
202
Street address
瀬戸町明神字丸山85番地1
Organisation type
301
Processing type
71
Correction type
1
Status
Representative
Capital
Employees
632
Employees (male)
486
Employees (female)
146
Business summary
医薬品原料、食品添加物、高純度化学品の製造、販売
Website URL
https://tomitaph.co.jp/
Year founded
Business category
E:製造業
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2025-06-30
Key information
1480001005057
§09

Sources & updates

SOURCES
↑